Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results
Date:8/4/2011

$3.5 million and $37.7 million of which was recognized, respectively, as collaboration revenue for the three and six months ended June 30, 2011. The remaining $22.3 million is deferred revenue and will be amortized as collaboration revenue over the estimated obligation periods.

Research and development (R&D) expenses for the three and six months ended June 30, 2011 were $7.3 million and $18.8 million, respectively, compared to $8.2 million and $18.0 million, respectively, for the same periods in 2010. For the three months ended June 30, 2011 compared to the same period in 2010, the decrease in R&D expenses was due primarily to a decrease in clinical and other project expenses to support the LEVADEX Phase 3 clinical program, partially offset by an increase in personnel related expenses including stock-based compensation. For the six months ended June 30, 2011 compared to the same period in 2010, the increase in R&D expenses was due primarily to an increase in personnel related expenses including stock-based compensation, partially offset by a decrease in other expenses.  

Sales, general and administrative (SG&A) expenses for the three and six months ended June 30, 2011 were $4.8 million and $9.6 million, respectively, compared to $3.9 million and $7.8 million, respectively, for the same periods in 2010. For the three and six months ended June 30, 2011 compared to the same periods in 2010, the increase in SG&A expenses was due primarily to an increase in personnel related expenses including stock-based compensation, and an increase in professional services expenses.

For the three and six months ended June 30, 2011, non-cash stock-based compensation and depreciation expense were approximately $2.0 million and $4.4 million, respectively.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
2. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
4. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
6. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
7. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
9. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
10. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
11. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... WILSONVILLE, Ore. , Aug. 29, 2014 /PRNewswire-iReach/ ... its Accessory (Axilla) Strap for the SAM Junctional ... SAM Medical Products announced ... a voluntary recall to address a potential issue ... strap used for the Axilla application of the ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
(Date:9/1/2014)... -- Watching action shows on TV may be bad for ... more snack food while watching action films and programs than ... "We find that if you,re watching an action movie while ... Aner Tal, of the Cornell Food and Brand Lab, said ... distracting the program is, the more you will eat." ...
(Date:9/1/2014)... 01, 2014 More than 200 Lipitor ... a federal litigation that continues to progress in the ... LLP reports. , A federal Case List published ... the widely-used cholesterol medication by plaintiffs who developed Type ... claims, Pfizer Inc. failed to adequately warn patients and ...
(Date:9/1/2014)... Spain Monday 1 September 2014: Daily fruit consumption ... to 40%, according to research presented at ESC Congress ... findings from the seven year follow-up study of nearly ... that the more fruit people ate, the more their ... including ischaemic heart disease (IHD) and stroke, is the ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... shared responsibility to a whole new level. Six ... $2 trillion in healthcare costs over the next decade. ... within our grasp.Blue Shield of California has long advocated ... are pleased that these groups are embracing the challenge ...
... 11, 2009 Iron chelating drugs have been heavily ... a form of blood cancer often treated with blood ... the body, are highly expensive and potentially toxic. A ... finds that their increased use has been propagated ...
... 11 Stephen J. Ubl, president and CEO of ... statement regarding today,s White House announcement of an industry ... are very pleased to join with President Obama and ... improving access to affordable, quality health care. As ...
... -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: GNPH) (the "Company"), ... People,s Republic,of China, today announced that its stock will ... the new ticker symbol "JGBO" as of May 12, ... symbol "GNPH" at the,end of May 11, 2009. , ...
... BlueCross BlueShield Give 40 in District Opportunity to Help Community Prevent HIV/AIDS ... ... and Education ( SHIRE ), Inc., is reaching out to 40 young ... help prevent the spread of HIV and AIDS and childhood obesity. ...
... Medical TechnologyWASHINGTON, May 11 Patients from across the ... about how medical technology has helped improve or save ... House of Representatives Energy & Commerce Committee hearing on ... repeal the Food and Drug Administration,s (FDA) preemption authority. ...
Cached Medicine News:Health News:AdvaMed Pleased to Work with the White House to Advance Health Reform 2Health News:Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 3Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 4Health News:Patients Call for Continued FDA Preemption Authority 2Health News:Patients Call for Continued FDA Preemption Authority 3Health News:Patients Call for Continued FDA Preemption Authority 4
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
... LeibingerTitanium Microplus System is a ... skeletal fixation armamentarium. It may ... vault, nasal, zygomatic and orbital ... especially where increased strength over ...
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Medicine Products: